EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?

Zachary Bloomgarden iD

Journal of Diabetes · 2023-09 · 15 (9) · 712-713

DOI: 10.1111/1753-0407.13469 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Diabetes, online erschienen am 19.09.2023. Verfasst von Zachary Bloomgarden. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 ReceptorHumans

Substanzen

Glucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes, and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Zachary Bloomgarden

Zitieren

APA

Bloomgarden, Z. (2023). Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?. Journal of Diabetes, 15(9), 712-713. https://doi.org/10.1111/1753-0407.13469

Vancouver

Bloomgarden Z. Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?. Journal of Diabetes. 2023;15(9):712-713. doi:10.1111/1753-0407.13469

BibTeX
@article{Bloomgarden2023,
  author = {Bloomgarden, Zachary},
  title = {Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?},
  journal = {Journal of Diabetes},
  year = {2023},
  volume = {15},
  number = {9},
  pages = {712--713},
  doi = {10.1111/1753-0407.13469}
}
Kostenlos starten →